
Fisher & Paykel Healthcare
Manufacturer, designer and marketer of products.
Date | Investors | Amount | Round |
---|---|---|---|
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
* | N/A | Post IPO Equity | |
Total Funding | 000k |
NZD | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | (16 %) | (3 %) | 11 % | (27 %) | 75 % | 12 % | 11 % |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | 37 % | 27 % | 21 % | 51 % | 32 % | 34 % | 35 % |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | 23 % | 16 % | 8 % | 29 % | 19 % | 20 % | 21 % |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
R&D % of revenue | 9 % | 11 % | 11 % | 18 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
What began in 1934 as an appliance import business by founders Woolf Fisher and Maurice Paykel, evolved into a global leader in medical devices. The shift into healthcare started in the late 1960s from a need identified by Dr. Matt Spence at Auckland Hospital. He saw that patients on mechanical ventilators suffered from dry tracheas and sought a solution. This led to a collaboration with engineers Alf Melville and Dave O'Hare from Fisher & Paykel Industries. The result was a prototype humidifier, ingeniously crafted from a fruit-preserving jar. Fisher & Paykel's appliance division took this prototype and turned it into a manufactured product, selling the first respiratory humidifier in 1970. This marked the company's entry into the healthcare sector, which grew steadily over the following decades. A major turning point occurred in 2001 when Fisher & Paykel Industries split its operations. Fisher & Paykel Healthcare Corporation Ltd. became a separate, publicly listed company on the New Zealand and Australian stock exchanges, a move that allowed the healthcare business to focus on its specialized market. Today, the company designs and manufactures a wide range of products for respiratory care, acute care, and the treatment of obstructive sleep apnea, sold in about 120 countries.